Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation
Jörg Reimann,
Reinhold Schirmbeck,
Corresponding Author
Jörg Reimann
Department of Medical Microbiology and Immunology, University of Ulm, Ulm, Germany
Jörg Reimann, Department of Medical Microbiology and Immunology University of Ulm Helmholtzstr, 8/1 D-89081 Ulm Germany Fax: 49 731 503 3654 e-mail: [email protected]Search for more papers by this authorReinhold Schirmbeck
Department of Medical Microbiology and Immunology, University of Ulm, Ulm, Germany
Search for more papers by this author
Jörg Reimann,
Reinhold Schirmbeck,
Corresponding Author
Jörg Reimann
Department of Medical Microbiology and Immunology, University of Ulm, Ulm, Germany
Jörg Reimann, Department of Medical Microbiology and Immunology University of Ulm Helmholtzstr, 8/1 D-89081 Ulm Germany Fax: 49 731 503 3654 e-mail: [email protected]Search for more papers by this authorReinhold Schirmbeck
Department of Medical Microbiology and Immunology, University of Ulm, Ulm, Germany
Search for more papers by this authorAcknowledgements
We are very grateful for critical comments, preprints, discussions and suggestions from Drs H.-G. Ljunggren (Stockholm, Sweden), M.-J, Wick (Lund, Sweden), F. Dice (Boston, USA), T. H. Hansen (St Louis, USA), J. Yewdell (Bechesda, USA), G. Hammerling (Heidelberg, Germany), and A. Mowat (Glasgow, Scotland).
Abstract
Summary: The concept of distinct endogenous and exogenous pathways for generating peptides for MHC-I and MHC-II-restricted presemation to CD4+ or CD8+ T cells fits well with the bulk of experimental data. Nevertheless, evidence is emerging for alternative processing pathways that generate peptides for MHC-I-restricted presentation. Using a well characterized, particulate viral antigen of prominent medical importance (the hepatitis B surface antigen), we summarize our evidence that the efficient, endolysosomal processing of exogenous antigens can lead to peptide-loaded MHC-I molecules. In addition, we describe evidence for endolysosomal processing of mutant, stress protein-bound, endogenous antigens that liberate peptides binding to (and presented by) MHC-I molecules. The putative biological role of alternative processing of antigens generating cytotoxic T lymphocyte-stimulating epitopes is discussed.
References
- 1 Germain RN. Antigen processing and presentation. In: WE Paul, ed. Fundamental immunology, Philadelphia. New York : Lippincott-Raven; 1999, p. 287–341.
- 2 Pamer EG, Cresswell P. Mechanisms of MHC class J-restricted antigen processing. Annu Rev Immunol 1998; 16: 323–358.
- 3 Momburg F, Hammerling GJ. Generation and TAP-mediated transport of peptides for major histocompatibility complex class I molecules. Adv Immunol 1998; 68: 191–256.
- 4 Raz E, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses, Proc Natl Acad Sci USA 1994; 91: 9519–9523.
- 5 Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997; 9: 1897–1906.
- 6 Ulmer JB, et al. Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity. Vaccine 1997; 15: 839–841.
- 7 Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188: 1075–1082.
- 8 Kurts C, Heath WR, Carbone FR, Allison JP, Miller JFAP, Kosaka H. Constitutive class I-restrieted exogenous presentation of self antigens in vivo. J Exp Med 1996; 184: 923–930.
- 9 Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibihty complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998; 188: 409–414.
- 10 Kurts C, et al. CD4+ T cell help impairs CD8+ T eel) deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997; 186: 2057–2062.
- 11 Heath WR, Kurts C, Miller JF, Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998; 187: 1549–15553.
- 12 Goletz TJ, Klimpel KR, Leppla SH, Keith JM, Berzofsky JA. Delivery of antigens to the MHC dass I pathway using bacterial toxins. Hum Immunol 1997; 54: 129–136.
- 13 Schirmbeck R, Zerrahn J, Kuhrober A, Kury E, Deppert W, Reimann J. Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ CD4- CD8+ cytotoxic T lymphocytes in mice. Eur J Immunol 1992; 22: 759–766.
- 14 Schirmbeck R, Zerrahn J, Kuhröber A, Deppert W, Reimaim J. Immunization of mice with the N-terminal (1-272) fragment of simian virus 40 large T-antigen (without adjuvants) specifically primes cytotoxic T lymphocytes. Eur J Immunol 1993; 23: 1528–1534.
- 15 Schirmbeck R, Melber K, Mertens T, Reimann J. Selective stimulation of murine cytotoxic T ceil and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigen. Eur J Immunol 1994; 24: 1088–1096.
- 16 Schirmbeck R, Böhm W, Reimann J. Injection of detergent-denatured ovalbumin primes murine class I-restricted cytotoxic T cells in vivo. Eur J Immunol 1994; 24: 2068–2072.
- 17 Weidt G, Utermohlen O, Zerrahn J, Reimann J, Deppert W, Lehmann-Grube F. CD8+ T lymphocyte-mediated antiviral immunity in mice as a result of injection of recombinant viral proteins. J Immunol 1994; 153: 2554–2561.
- 18 Schirmbeck R, Demi L, Melber K, Wolf H, Wagner R, Reimann J. Priming of class I-restricted cycotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 1995; 13: 857–865.
- 19 Allsopp CE, et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 1996; 26: 1951–1959.
- 20 Diminsky D, Schirmbeck R, Reimann J, Barenholz Y. Comparison between surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997; 15: 637–647.
- 21 Schirmbeck R, Melber K, Kuhrober A, Janowicz ZA, Reimann J. Immunization with soluble hepatitis B virus surface (S) protein particles elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J Immunol 1994; 152: 1110–1119.
- 22 Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J Virol 1994; 68: 1418–1425.
- 22a Wild J, Grusby MJ, Schirmbeck R, Reiman J. Priming MHC-I-restricted, cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell-dependent. J Immunol 1999; 163: 1880–1887.
- 23 Davis HL, Michel M-L, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993; 2: 1847–1851.
- 24 Fuller JT, Fuller DH, McCabe D, Haynes JR. Widera G. Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization. Ann NY Acad Sci 1995; 772: 282–284.
- 25 Michel M-L, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995; 92: 5307–5311.
- 26 Böhm W, Kuhrober A. Paier T, Mertens T, Reimann J, Schirmbeck R. DNA VEC constructs that prime hepatitis B surface antigen-specific cytotoxic T lymphocytes and antibody responses in mice after intramuscular injection. J Immunol Methods 1996; 193: 29–40.
- 27 Davis HL, Mancini M, Michel M-L, Whalen RG. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine 1996; 14: 910–915.
- 28 Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997; 71: 169–178.
- 29 Geissler M, Tokushige K, Chante CC. Zurawski VRJ, Wands JR. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization. Gastroenterology 1997; 112: 1307–1320.
- 30 Davis HL, Schirmbeck R, Reimann J, Whalen RG. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to hepatitis B virus surface antigen. Hum Gene Ther 1995; 6: 1447–1456.
- 31 He XS, Chen HS, Chu K, Rivkina M, Robinson WS. Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. Proc Natl Acad Sci USA 1996; 93: 7274–7278.
- 32 Vitiello A, et al. Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance. Eur J Immunol 1997; 27: 671–678.
- 33 Geissler M, Schirmbeck R, Reimann J, Blum HE, Wands JR. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice. Hepatology 1998; 28: 202–210.
- 34 Le BS, et al. In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis E surface antigen. Virology 1998; 240: 304–315.
- 35 Böhm W, Mertens T, Schirmbeck R, Reimann J. Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses. Vaccine 1998; 16: 949–954.
- 36 Wild J, et al. Polyvalent vaccination against hepatitis B surface and core antigen using dicistronic expression plasmids. Vaccine 1998; 16: 353–360.
- 37 Schirmbeck R, Bohm W, Ando K-I, Chisari FY, Reimann J. Nucleic acid vaccination primes hepatitis B surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol 1995; 69: 5929–5934.
- 38 Bohm W. Thoma S, Leithäuser F, Moller P, Schirmbeck R, Reimann J. T cell-mediated, IFNγ -facilitated rejection of murine B16 melanomas. J Immunol 1998; 161: 897–908.
- 39 Schirmbeck R, Bohm W. Reimann J. DNA vaccination primes MHC dass l-restricted simian virus 40 large tumor antigen-specific cytotoxic T lymphocytes in H-2d mice that reject syngeneic tumors, J Immunol 1996; 157: 3550–3558.
- 40 Schirmbeck R. Melber K, Reimann J. Enhancing Kd-restricted cytotoxic T cell responses to exogenous hepatitis B surface antigen in ‘low’ responder' mice. Int Immunol 1999; 11: 1093–1102.
- 41 Ishikawa T, Kono DH, Fowler P, Theofilopoulos AN. Kakumu S, Chisari FV Polyclonality and multispecificity of the GTL response to a single viral epitope. J Immunol 1998; 161: 5842–5850.
- 42 Schirmbeck R, Wild J, Reimann J. Similar as well as distinct MHC-1-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen (HBsAg). Eur J Immunol 1998; 28: 4149–4161.
10.1002/(SICI)1521-4141(199812)28:12<4149::AID-IMMU4149>3.0.CO;2-D CASPubMedWeb of Science®Google Scholar
- 43 Böhm W, et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J Immunol 1995; 155: 3313–3321.
- 44 Wagner R, Demi L. Schirmbeck R, Reimann J, Wolf H. Induction of a MHG class I-restricted, CD8+ cytolytic T cell response by chimeric HIV-1 virus-like particles in vivo. Implications on HIV vaccine development. Behring Inst Mitt 1994; 95: 23–34.
- 45 Demi L, Schirmbeek R, Reimann J, Wolf H. Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 1997; 235: 26–39.
- 46 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29–60.
- 47 Kuhröber A, et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2d mice. J Immunol 1996; 156: 3687–3695.
- 48 Kuhröber A. Wild J. Pudollek HP, Chisari FV Reimann J. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes. Int Immunol 1997; 9: 1203–1212.
- 49 Schirmbeck R, Melber K, Reimann J. Hepatitis B virus surface particles are processed in a novel endosomal pathway for MHC class I-restricted epitope presentation. Eur J Immunol 1995; 25: 1063–1070.
- 50 Schirmbeck R, Reimann J. Recycling. ‘empty’ Ld molecules capture peptides from endocytosed, exogenous antigens for MHC class I-restricted presentation. Eur J Immunol 1996; 26: 2812–2821.
- 51 Lie W-R, Myers NB. Gorka J. Rubocki RJ, Connolly JM, Hansen TH. Peptide ligand-induced conformation and surface expression of the Ld class I MHC molecule. Nature 1990; 344: 439–441.
- 52 Lie W-R, Myers NB. Connolly JM, Gorka I, Lee DR, Hansen TH. The specific binding of peptide ligand to Ld class I major histocompatibility complex molecules determines their antigenic structure. J Exp Med 1991; 173: 449–459.
- 53 Smith JD, Lie W-R, Gorka J, Kindle CS, Myers NB, Hansen TH. Disparate interaction of peptide ligand with nascent versus mature class I major histocompatibihty complex molecules: comparisons of peptide binding to alternative forms of Ld in cell lysates and the cell surface. J Exp Med 1992; 175: 191–202.
- 54 Smith JD, Lie W-R, Gorka J, Myers NB, Hansen TH. Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous β2 -microglobulin. Proc Natl Acad Sci USA 1992; 89: 7767–7771.
- 55 Smith JD, Myers NB. Gorka J, Hansen TH. Model for the in vivo assembly of nascent Ld dass I molecules and for the expression of unfolded Ld molecules at the cell surface. J Exp Med 1993; 178: 2035–2046.
- 56 Tse DB, Pernis B. Spontaneous internalization of dass I major histocompatibility complex molecules in T lymphoid cells. J Exp Med 1984; 159: 193–207.
- 57 Machy P. Truneh A, Gennaro D, Hoffstein S. Endocytosis and de novo expression of major histocompatibility complex encoded dass I molecules: kinetic and ultrastruetural studies. Eur J Cell Biol 1987; 45: 126–136.
- 58 Dasgupta JD, Watkins S, Slayter H, Yunis EJ. Receptor-like nature of dass I HLA: endocytosis via coated pits. J Immunol 1988; 141: 2577–2580.
- 59 Reid PA, Watts C. Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature 1990; 346: 655–657.
- 60 Hochman JH, Jiang H, Matyus L, Edidin M, Pernis B. Endocytosis and dissociation of class I MHC molecules labeled with fluorescent β-2 microglobulin. J Immunol 1991; 146: 1862–1867.
- 61 Abdel Motal UM, et al. Major histocompatibility complex class I-binding peptides are recycled to the cell surface after internalization. Eur J Immunol 1993; 23: 3224–3229.
- 62 Machold RP, Ploegh HL. Intermediates in the assembly and degradation of class I major histocompatibility complex (MHG) molecules probed with free heavy chain-specific monoclonal antibodies. J Exp Med 1996; 184: 2251–2259.
- 63 Vega MA, Strominger JL. Constitutive endocytosis of HLA dass 1 antigens requires a specific portion of the intracytoplasmic tail that shares structural features with other endocytosed molecules. Proc Natl Acad Sd USA 1989; 86: 2688–2692.
- 64 Abdel Motal UM. Sentman CL, Zhou X, Robinson PJ, Dahmen J, Jondal M. Glycosylphosphatidylinositol-linked Db does not induce an influenza-specific cytotoxic T lymphocyte response or recycle membrane-bound peptides. Eur J Immunol 1995; 25: 1121–1124.
- 65 Cariappa A, et al. Glycosylphosphatidylinositol-anchored H-2Db molecules are defective in antigen processing and presentation to cytotoxic T lymphocytes. Eur J Immunol 1996; 26: 2215–2224.
- 66 Zitvogel L, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594–600.
- 67 Allen H. Fraser J, Flyer D, Calvin S, Flavell RH. β2–microglobulin is not required for cell surface-expression of the murine class I histocompatibility antigen H- 2 D1b or of a truncated H-2 Db. Proc Natl Acad Sci USA 1986; 83: 7447–7451.
- 68 Pickl WF Majdic O, Fae I. Reuschel R, Holter W, Knapp W. The soluble pool of β2-microglobulin free HLA dass I β-chains. Qualitative and quantitative characterization. J Immunol 1993; 151: 2613–2622.
- 69 Carreno BM, Hansen TH. Exogenous peptide ligand influences the expression and half-life of free HLA dass I heavy chains ubiquitously detected at the ceil surface. Eur J Immunol 1994; 24: 1285–1292.
- 70 Machold RP Andree S, Van Kaer L, Ljunggren H-G, Ploegh HL. Peptide influences the folding and intracellular transport of free major histocompatibility complex dass I heavy chains, J Exp Med 1995; 181: 1111–1122.
- 71 Lagaudriere GG, Lebel BS, Wiertz F, Ploegh HL. Fradelizi D. Conjeaud H. The tetraspanin protein CD82 associates with both free HLA dass I heavy chain and heterodimeric β2-microglobulin complexes. J Immunol 1997; 158: 2790–2797.
- 72 Wang Z, Arienti E, Parmiani G, Ferrone S. Induction and functional characterization of β2-microglobuhn (β2-m)-free HLA dass I heavy chains expressed by β2-m-deficient human FO-1 melanoma cells. Eur J Immunol 1998; 28: 2817–2826.
10.1002/(SICI)1521-4141(199809)28:09<2817::AID-IMMU2817>3.0.CO;2-M CASPubMedWeb of Science®Google Scholar
- 73 Day PM, Esquivel F. Lukszo J, Bennink JR, Yewdell JW. Effect of″ TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules. Immunity 1995; 2: 137–147.
- 74 Ljunggren H-G, et al. Empty MHC class I molecules come out in the cold. Nature 1990; 346: 476–480.
- 75 De Bruijn MLH, Schuhmacher TNM, Nidand JD, Ploegh HL, Kast WM, Melief GJM. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses, Eur J Immunol 1991; 21: 2963–2970.
- 76 Bernabeu C, van de Rijn M, Lerch PG, Terhorst C. β2-microglobulin from serum associates with MHC class I antigens on the surface of cultured cells. Nature 1984; 308: 642–645.
- 77 Perarneau B, Siegrist C-A, GiUet A, Vincent C, Kimura S. Lemonnier FA. β2-microglobulin restriction of antigen presentation. Nature 1990; 346: 751–753.
- 78 Rock KL, Rothstein LE, Gamble SR, Benacerraf B. Reassociation with β2-microglobulin is necessary for Kb class I major histocompatibility complex binding of exogenous peptides. Proc Natl Acad Sd USA 1990; 87: 7517–7521.
- 79 Vitidlo A. Potter TA, Sherman LA. The role of β2-microglobulin in peptide binding by dass I molecules. Science 1990; 250: 1423–1426.
- 80 Kozlowski S, et al. Excess β2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature 1991; 349: 74–77.
- 81 Rock KL, Gamble S, Rothstein L, Gramm C, Benacerraf B. Dissociation of β2-microglobulin leads to the accumulation of a substantial pool of inactive class I MHC heavy chains on the cell surface. Cell 1991; 65: 611–620.
- 82 Wolf PR. Cook RG. The class I-b molecule Qa-1 forms heterodimers with H-2Ld and a novel 50-kD glycoprotein encoded centromeric to I-E β. J Exp Med 1995; 181: 657–668.
- 83 Schirmbeck R, Thoma S, Reimann J. Processing exogenous HBsAg particles for Ld-restricted epitope presentation depends on exogenous β2m. Eur J Immunol 1997; 27: 3471–3484.
- 84 Prigozy TI, et al. The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T ceils by CD l b molecules. Immunity 1997; 6: 187–197.
- 85 Schirmbeck R, Bohm W. Melber K, Reimann J. Processing of exogenous heat-aggregated (denatured) or particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J Immunol 1995; 155: 4676–4684.
- 86 Snzue K, Young R. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24, J Immunol 1996; 156: 873–879.
- 87 Schirmbeck R. Reimann J. Peptide transporter-independent, stress protein-mediated endosomal processing of endogenous protein antigens for major histocompatibility complex class I presentation. Eur J Immunol 1994; 24: 1478–1486.
- 88 Schirmbeck R, Bohm W, Reimann J. Stress protein (hsp73) -mediated, TAP-independent processing of endogenous, truncated SV40 large T antigen for Db-restricted peptide presentation. Eur J Immunol 1997; 27: 2016–2023.
- 89 Schirmbeck R, Gerstner O. Reimann J. Truncated or chimeric endogenous protein antigens gain immunogenicity for B cells by stress protein-facilitated expression. Eur J Immunol 1999; 29: 1740–1749.
10.1002/(SICI)1521-4141(199905)29:05<1740::AID-IMMU1740>3.0.CO;2-X CASPubMedWeb of Science®Google Scholar
- 90 Grussenmeyer J, Scheidtmann KH. Hutchinson MA, Eckhart W Walter G. Complexes of polyoma virus medium T antigen and cellular proteins. Proc Natl Acad Sci USA 1985; 82: 7952–7954.
- 91 Walter G, Carbone A, Welch WJ. Medium tumor antigen of polyoma virus transformation-defective mutant NG5 9 is associated with 73-kilodalton heat shock protein. J Virol 1987; 61: 405–410.
- 92 Hightower LE, Sadis SE, Takenaka IM. Interaction of vertebrate hsc70 and hsp70 with unfolded proteins and peptides. In: RI. Morimoto A Tissieres, G Georgopoulos, eds. The biology of heat shock proteins and molecular chaperones. Cold Spring Harbor : CSHL Press: 1994. p, 179–207.
- 93 Dice JF. Agarraberes F. Kirven-Brooks M. Terlecky LJ, Terlecky SR. Heat shock 70-kD proteins and lysosomal proteolysis. In: RI Morimoto, A Tissieres, C Georgopoulos, eds. The biology of heat shock proteins and molecular chaperones. Cold Spring Harbor : GSHL Press: 1994. p. 137–151.
- 94 Dice JF, Terlecky SR. Selective degradation of cytosolic proteins by lysosomes. In: AJ Ciechanover, AL Schwartz, eds. Cellular proteolytic systems. New York : Wiley-Liss; 1994. p. 55–64.
- 95 Hayes SA. Dice JF. Roles of molecular chaperones in protein degradation. J Cell Biol 1996; 132: 255–258.
- 96 Chiang H-L, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 1989; 246: 382–385.
- 97 Terlecky SR. Chiang H-L, Olson TS. Dice JF Protein and peptide binding and stimulation of in vitro lysosomal proteolysis by the 7 3 -kDa heat shock cognate protein. J Biol Chem 1992; 267: 9202.
- 98 Cuervo AM. Knecht E, Terlecky SR, Dice JF. Activation of a selective pathway of lysosomal proteolysis in rat liver by prolonged starvation. Am J Physiol 1995; 269: C1200–1208.
- 99 Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 1996; 273: 501–503.
- 100 Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs). A major source of antigenic peptides for MHC class I molecules? J Immunol 1996; 157: 823–1826.
- 101 DeNagel DC. Pierce SK. Heal shock proteins in immune responses. Crit Rev Immunol 1993; 13: 71–81.
- 102 Sargent CA, Dunham I, Trowsdale J, Campbell RD. Human major histocompatihility complex contains genes for the major heat shock protein Hsp70. Proc Natl Acad Sci USA 1986; 86: 1986–1972.
- 103 Nieland TJF, Tan MCA, van Muijen MM. Koning F, Kruisbeek AM, van Bleek GM. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc Natl Acad Sci USA 1996; 93: 6135–6139.
- 104 Li Z. Srivastava PK. Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation, EMBO J 1993; 12: 3143–3151.
- 105 Srivastava PK. Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 1993; 62: 153–177.
- 106 Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993; 178: 1391–1396.
- 107 Srivastava PK, Udono H, Blachere NE. Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming, Immunogenetics 1994; 39: 93–98.
- 108 Udono H, Srivastava PK. Comparison of tumor-specific immunogenicity of stress-induced protein gp96. hsp90, and hsp70, J Immunol 1994; 152: 5398–5403.
- 109 Udono H, Levey DL. Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 1994; 91: 3077–3081.
- 110 Arnold D, Faath S. Rammensee HG, Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 1995; 182: 885–889.
- 111 Roman E, Moreno C. Synthetic peptides non-covalently bound to bacterial hsp70 elicit peptide-specific T-cell responses in vivo. Immunology 1996; 88: 487–492.
- 112 Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies WA. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 1994; 180: 1415–1425.
- 113 Suto R. Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269: 1585–1588.
- 114 Wood P, Elliott T. Glycan-regulated antigen processing of a protein in the endoplasmic reticulum can uncover cryptic cytotoxic T cell epitopes. J Exp Med 1998; 188: 773–778.
- 115 Bacik I, et al. Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticuium to the cytosol. J Exp Med 1997; 186: 479–487.
- 116 Snyder HL, et al. Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex dass I antigen processing. J Exp Med 1997; 186: 1087–1098.
- 117 Snyder HL, Badk I. Yewdell JW. Behrens TW, Bennink JR. Promiscuous liberation of MHG-class I-binding peptides from the G termini of membrane and soluble proteins in the secretory pathway. Eur J Immunol 1998; 28: 1339–1346.
10.1002/(SICI)1521-4141(199804)28:04<1339::AID-IMMU1339>3.0.CO;2-B CASPubMedWeb of Science®Google Scholar
- 118 Gil-Torregrosa BC. Castano AR. Dd Val M. Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J Exp Med 1998; 188: 1105–1116.
- 119 Mortimore GE, Kadowaki M. Autophagy: its mechanism and regulation. In: AJ Ciechanover, AL Schwartz, eds. Cellular proteolytic systems. New York : Wiley-Liss; 1994. p. 65–87.
- 120 Lindner R, Unanue ER. Distinct antigen MHG class 11 complexes generated by separate processing pathways, EMBO J 1996; 15: 6910–6920.
- 121 Griffin JP. Chu R. Harding CV. Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. J Immunol 1997; 158: 1523–1532.
- 122 Ma C, Blum JS. Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in dass II-restricted antigen presentation. J Immunol 1997; 158: 1–4.
- 123 Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules, Annu Rev Immunol 1997; 15: 821–850.
- 124 Sigal LJ. Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haemopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77–80.
- 125 Bevan MJ. Minor H. Antigens introduced on H-2 different stimulating cells cross -react at the cytotoxic T cell level during in vivo priming. J Immunol 1976; 117: 2233–2238.
- 126 Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay J Exp Med 1976; 143: 1283–1288.
- 127 Bevan MJ. In a radiation chimera, host H-2 antigens determine immune responsiveness of donor cytotoxic cells. Nature 1977; 269: 417–418.
- 128 Gordon RD, Mathieson BJ, Samdson LE, Boyse EA, Simpson E. The effect of allogeneic presensitization on H-Y graft survival and in vitro cell-mediated responses to H-y antigen, J Exp Med 1976; 144: 810–820.
- 129 Gooding L, Edwards GB. H-2 antigen requirements in the in vitro induction of SVO-specific cytotoxic T lymphocytes. J Immunol 1980; 124: 1258–1262.
- 130 Huang AY. Golumbek P Ahmadzadeh M. Jaffee E, Pardoll D. Levitsky HL Role of bone marrow-derived cells in presenting MHC dass I-restricted tumor antigens. Science 1994; 264: 961–965.
- 131 Wu TC, Huang AY, Jaffee EM. Levitsky HI. Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995; 182: 1415–1421.
- 132 Carbone FR, Bevan MJ. Glass I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990; 171: 377–387.
- 133 Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996; 184: 1555–1560.
- 134 Doe B, Selby M, Barnett S, Baenziger J, Walker CM. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA 1996; 93: 8578–8583.
- 135 Ulmer JB, Deck RR, DeWitt GM. Donnhly JI, Liu MA. Generation of MHG class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996; 89: 59–67.
- 136 Iwasaki A, Torres CA, Ohaslii PS. Robinson HL. Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997; 159: 11–14.
- 137 Kurts C, Kosaka H, Carbone FR. Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J Exp Med 1997; 186: 239–245.
- 138 Bellone M, et al. Processing of engtilfed apoptotic bodies yields T cell epitopes. J Immunol 1997; 159: 5391–5399.
- 139 Albert ML. et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359–1368.
- 140 Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M. Vile RG, Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4: 581–587.
- 141 Rovere P, et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998; 161: 4467–4471.
- 142 Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328–332.
- 143 Pamer HG. Sijts AJ, Villanueva MS, Busch DH, Vijh S. MHC dass I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses. Immunol Rev 1997; 158: 129–136.
- 144 Darji A, Chakraborty T, Wehland J, Weiss S. TAP-dependent major histocompatibility complex class I presentation of soluble proteins using listeriolysin. Eur J Immunol 1997; 27: 1353–1359.
- 145 Mazzaccaro RJ, et al. Major histocompatibility class 1 presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1996; 93: 11786–11791.
- 146 Pfeifer JD, Wick MJ, Roberts RL. Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993; 361: 359–362.
- 147 Harding CV, et al. Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway. J Immunol 1995; 155: 1767–1775.
- 148 Wick MJ, Pfeifer JD. Major histocompatibility complex dass I presentation of ovalbumin peptide 257–264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Hur J Immunol 1996; 26: 2790–2799.
- 149 Svensson M. Stoddnger B, Wick MJ. Bone marrow-derived dendritic cells can process bacteria for MHG-I and MHG-II presentation to T cells. J Immunol 1997; 158: 4229–4236.
- 150 Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by dass I MHC molecules. J Immunol 1994; 153: 4925–4933.
- 151 Rock KL. Rothstein LE, Fleischacker C, Gamble SR. Inhibition of class I and class II MHG-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen. J Immunol 1992; 148: 3028–3033.
- 152 Kovacsovics Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993; 90: 4942–4946.
- 153 Kovacsovics Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class 1 molecules. Science 1995; 267: 243–246.
- 154 Raposo G, et al. B lymphocytes secrete antigen-presenting vesicles, J Exp Med 1996; 183: 1161–1172.
- 155 Nair S, Zhou X, Huang L, Rouse BT. Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. J Immunol Methods 1992; 152: 237–243.
- 156 Reddy R, Zhou F, Nair S, Huang L. Rouse BT In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol 1992; 148: 1585–1589.
- 157 Zhou F. Rouse BT, Huang L. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J Immunol 1992; 149: 1599–1604.
- 158 Collins DS, Findlay K, Harding CV. Processing of exogenous liposome -encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol 1992; 148: 3336–3341.
- 159 Yewdell JW, Bennink JR, Hosaka Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 1988; 239: 637–640.
- 160 Vinitsky A, Anton LC. Snyder HL, Orlowski M, Bennink JR, Yewdell JW. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing J Immunol 1997; 159: 554–564.
- 161 Wiktor TJ. Doherty PC. Koprowski H. In vitro evidence of cell-mediated immunity after exposure of mice to both live and inactivated rabies virus. Proc Natl Acad Sci USA 1977; 74: 334–338.
- 162 Reddehase MJ, Keil GM, Koszinowski UH. The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol 1984; 14: 56–61.
- 163 Liu T Zhou X. Orvell G, Lederer E, Ljunggren H-G, Jondal M. Heat-inactivated Sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo. J Immunol 1995; 154: 3147–3155.
- 164 Schrader JW Edelman GM. Joint recognition by cytotoxic T cells of inactivated Sendai virus and products of the major histocompatibility complex. J Exp Med 1977; 145: 523–539.
- 165 Zhou X, Berglund P, Zhao H. Liljestrom P, Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci USA 1995; 92: 3009–3013.
- 166 Zhou X, Glas R, Liu T, Ljunggren H-G, Jondal M. Antigen processing mutant T2 cells present viral anligen restricted through H-2Kb. Eur J Immunol 1993; 23: 1802–1808.
- 167 Zhou X, Glas R, Momburg F, Hammerling GJ, Jondal M, Ljtinggren H-G. TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T lymphocytes. Eur J Immunol 1993; 23: 1796–1801.
- 168 Sedlik C, Saron M-F, Sarraseca J, Lederc C. Recombinant parvovirus-like partides as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 1997; 94: 7503–7508.
- 169 Greenstone HL, et al. Chimeric papillomavirus virus-like partides elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998; 95: 1800–1805.
- 170 Griffiths JC. et al. Hybrid human immunodeficiency virus Gag partides as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag: V3 fusion. J Virol 1993; 67: 3191–3198.
- 171 Harris SJ, Gearing AJ, Layton GT, Adams SH, Kingsman AJ. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp1 20 following immunization with V3: Ty virus-like particles. Immunology 1992; 77: 315–321.
- 172 Layton GT, et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3: Ty-virus-like particles. J Immunol 1993: 151: 1097–1107.
- 173 Jin Y. Shih JWK, Berkower I. Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen. J Exp Med 1988; 168: 293–306.
- 174 Barnaba Y, Franco A, Aiberti A, Benvenuto R, Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature 1990; 345: 258–260.
- 175 Darji A, Chakraborty T Wehland J, Weiss S. Listeriolysin generates a route for the presentation of exogenous antigens by major histocompatibility complex dass I. Eur J Immunol 1995; 25: 2967–2971.
- 176 Zwickey HL, Potter TA. Peptide epitopes from noncytosolic Listeria monocytogenes can be presented by major hisiocompatibility complex class I molecules. Infect Immunol 1996; 64: 1870–1872.
- 177 Lee RS, et al. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur J Immunol 1998; 28: 2726–2737.
10.1002/(SICI)1521-4141(199809)28:09<2726::AID-IMMU2726>3.0.CO;2-W CASPubMedWeb of Science®Google Scholar
- 178 Goletz TJ, Klimpel KR. Arora N, Leppla SH, Keith JM, Berzofsky JA. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gpi 20-anthrax toxin fusion protein. Proc Natl Acad Sci USA 1997; 94: 12059–12064.
- 179 Ulmer JB, Donnelly JJ, Liu MA. Presentation of an exogenous antigen by major histocompatibility complex class I molecules. Eur J Immunol 1994; 24: 1590–1596.
- 180 Saron MF, Fayolle G, Sebo P, Ladant D, Ullmann A, Lederc C. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 1997; 94: 3314–3319.
- 181 Guermonprez P, Ladant D, Karimova G, Uilmann A. Lederc G. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC Class I antigen presentation pathway. J Immunol 1999; 162: 1910–1916.
- 182 Van Binnendijk RS, et al. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and dass II-restricted cytotoxic T cell recognition. J Exp Med 1992; 176: 119–128.
- 183 Newman MJ, et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol 1992; 148: 2357–2362.
- 184 Raychaudhuri S, Tonks M. Carbone F, Ryskamp T, Morrow WJ, Hanna N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci USA 1992; 89: 8308–8312.
- 185 Tevethia SS, Flyer DC. Tjian R. Biology of simian virus 40(SV40) transplantation antigen (TrAg). VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein), Virology 1980; 107: 13–23.
- 186 Yamada A, Ziese MR. Young JF, Yamada Y, Ennis FA. Influenza virus hemagglutinin-specific cytotoxic T cell response induced by polypeptide produced in Escherichia coll. J Exp Med 1985; 162: 663–674.
- 187 Wraith DC, Vessey AE. Influenza virus-specific cytotoxic T-cell recognition: stimulation of nucleoprotein-specific clones with intact antigen. Immunology 1986; 59: 173–180.
- 188 Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 1987; 68: 433–440.
- 189 Staerz UD, Karasuyama H, Garner AM. Cytotoxic T lymphocytes against a soluble protein. Nature 1987; 329: 449–451.
- 190 Suss G, Pink JR. A recombinant malaria protein that can induce Th1 and CD8+ T cell responses without antibody formation. J Immunol 1992; 149: 1334–1339.
- 191 Bachmann et al. Induction of protective cytotoxic T cells with viral proteins. Eur J Immunol 1994; 24: 2128–2236.
- 192 Bachmann ME, et al. TAPl -independent loading of dass 1 molecules by exogenous viral proteins. Eur J Immunol 1995; 25: 1739–1743.
- 193 Doe B. Steimer KS. Walker CM. Induction of HlV-1 envelope (gp 120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Eur J Immunol 1994; 24: 2369–2376.
- 194 Speidel K. et al. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997; 27: 2391–2399.
- 195 Blachere NE, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186: 1315–1322.
- 196 Roman E, Moreno C. Delayed-type hypersensitivity elicited by synthetic peptides completed with Mycobacterium tuberculosis hsp 70. Immunology 1997; 90: 52–56.
- 197 Ciupitu AM, et al. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med 1998; 187: 685–691.
- 198 Suzue K, Zhou X, Eisen HN. Young R. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibihty complex class I presentation pathway. Proc Natl Acad Sci USA 1997; 94: 13146–13151.
